✦ LIBER ✦
Cost-Consequence Analysis of a Treatment Strategy Including Ponatinib Compared to a Treatment Strategy Including Only the 2nd Generation Tyrosine Kinase Inhibitors (2g TKIs), Dasatinib or Nilotinib, in Resistant Patients with Philadelphia Chromosome-Positive (Ph+) Leukemia, in Italy
✍ Scribed by Chiroli, S.; Furneri, G.; Pane, F.
- Book ID
- 122283823
- Publisher
- John Wiley and Sons
- Year
- 2013
- Tongue
- English
- Weight
- 79 KB
- Volume
- 16
- Category
- Article
- ISSN
- 1098-3015
No coin nor oath required. For personal study only.